Arabic Arabic English English French French German German
dark

Novo Nordisk Takes Over Prothena’s ATTR Amyloidosis Business for $1.2 Billion

Novo Nordisk will take over Prothena’s wholly-owned subsidiary and gain full global intellectual property rights and other related rights for the latter’s ATTR amyloidosis business and pipeline.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

‘Wasfaty’ Service Activated in King Saud Medical City

Next Post

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

Related Posts
Total
0
Share